20150318 smb hve quirem medical jan sigger

Click here to load reader

  • date post

  • Category


  • view

  • download


Embed Size (px)

Transcript of 20150318 smb hve quirem medical jan sigger

  • March 2015

    QuiremSpheres The Next Generation Microspheres for Radioembolisation

    Treat what you see and see what you treat

  • Agenda

    Company Profile

    Management Team

    Cancer in the liver

    The radioembolisation market


    Company timeline

    Main start-up challenges


  • Spin-off in 2013 from the University Medical Center Utrecht

    20 years of development on Holmium microspheres

    Superior proposition in fast growing radioembolisation market for liver malignancies

    Higher dose rate ensures more effective tumor kill

    Unique imaging capabilities enable personalized, real-time, image-guided treatment

    Supported by state-of-the-art administration device and industry first SW treatment planning & evaluation solution

    Preparing for product launch early 2015

    Strong IP position

    Management team with proven track record

    Company ProfileSuperior proposition in fast growing market

  • Jan Sigger Chief Executive Officer

    Held senior management positions at Royal Dutch Shell and Akzo Nobel.

    Joint Nucletron, the global market leader in brachytherapy, as CFO in 2008.

    Transformed Nucletron into the fastest growing radiotherapy company and managed the sale from private equity ownership to Elekta AB in 2011.

    Jan Sigger

    Chief Executive Officer


    M: +31 6 20545977

    Management TeamQuirem Medical has a seasoned team with relevant experience

    Frank Nijsen Chief Scientific Officer

    Performed 20 years of research into Holmium microspheres.

    Led the successful valorisation of the Holmium technology and was

    instrumental in the creation of the spin-off company Quirem Medical.

    Holds as inventor many patents in the radioembolization field. Frank Nijsen

    Chief Scientific Officer



    M: +31 6 40675781

  • 5* Globocan 2012 data

    High medical needLife expectancy is low for both primary and metastasized liver cancer

  • Liver:

    70% portal vein

    30% hepatic artery


    99% hepatic artery

    Radioembolisation of the liverMaximising the dose to the tumor

  • MRI of distribution of

    paramagnetic QuiremSpheres - energy 1.84 MeV

    166Ho- energy 81 keV


    QuiremSpheresNeutron activation and characteristics

  • See what you treat and treat what you see

    Before treatment After treatment

    19 Gy135 Gy

    35 Gy

    19 Gy135 Gy

    35 Gy

    Anatomical MRI Nuclear imaging QuiremSpheres sensitive MRI

    Tumor 1Tumor 2

    Personalized local treatment Optimal radiation dose to the tumor Minimal side effects Treatment planning & evaluation

    (no more black box) Follow-up treatment if needed

    Imaging capabilities QuiremSpheres Enabling treatment planning & evaluation and real-time image guided treatment

  • 9Clinical evidence is growingSuccessful phase 1 study, phase 2 study almost completed, 3rd and 4th study started,

    5th study for intratumoral head & neck treatment recently approved

    Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): a phase 1, dose-escalation study

    Maarten Smits, Johannes Nijsen, Maurice van den Bosch, Marnix Lam, Maarten Vente, Willem Mali, Alfred van het Schip, Bernard Zonnenberg

    Lancet Oncology 2012 Oct;13(10):1025-34.

  • Main start-up challengesMake sure to timely address the key factors for success by creating:

    The right team (priority 1,2 and 3)

    The right information

    Business plan

    Financial plan

    IP landscape

    The right support




    The right partners



    The right investors

    Funding capabilities

    Time horizon



  • a personalized way to fight liver cancer